Craif Inc.

Craif Inc. is a forward-looking startup dedicated to revolutionizing the early cancer diagnosis landscape through advanced urine testing techniques. The company's slogan, "Empowering a new era of early, painless, and precise cancer diagnosis," encapsulates its mission to eradicate the loss of lives to cancer. Founded in 2018, Craif is operating in the Health Care industry, focusing on developing a society where cancer diagnosis is painless and accurate. Craif recognizes the critical importance of early cancer detection, acknowledging that it can amplify survival rates and significantly enhance outcomes. With numerous cancers remaining asymptomatic until they reach advanced stages, the need for regular and precise diagnostic tests is more crucial than ever. The company aims to address the shortcomings of current diagnostic methods, which often prove painful and lack the essential accuracy for consistent and early-stage detection. In its journey to fulfill its vision, Craif recently secured a significant milestone with its Series B investment on 22 April 2022, with Global Brain coming on board as the investor. This strategic partnership is a testament to the potential recognized by leading investors in Craif's groundbreaking approach to cancer diagnosis.